[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100461124":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":26,"centralContacts":36,"locations":45,"responsibleParty":188,"collaborators":191,"id":201,"slug":202,"hasResults":203,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":17,"eligibilityCriteria":207,"healthyVolunteers":203,"sex":208,"minAge":209,"maxAge":17,"enrollmentInfo":210,"targetDuration":17,"studyType":213,"phases":214,"briefSummary":216,"conditions":217,"keywords":219,"overallStatus":48,"whyStopped":17,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":232},{"fullName":5,"class":6},"University Hospital, Linkoeping","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention Arm","EXPERIMENTAL","Drug: Tinzaparin (Innohep®), solution for injection. Administration form: Subcutaneous injection. Dosage: 4500 IU (for subjects weighing below 90 kg) or 8000 IU (for subjects weighing 90 kg and above) daily for 21-28 weeks.",[13],"Drug: Tinzaparin Injectable Solution",{"label":15,"type":16,"description":17,"interventionNames":17},"Control Arm","NO_INTERVENTION",null,[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Tinzaparin Injectable Solution","Subcutaneous injection",[9],[25],"Innohep®",[27,30,32,34],{"name":28,"affiliation":5,"role":29},"Preben Kjölhede, MD, PhD","STUDY_CHAIR",{"name":31,"affiliation":5,"role":29},"Gabriel Lindahl, MD, PhD",{"name":33,"affiliation":5,"role":29},"Anna-Clara Spetz Holm, MD, PhD",{"name":35,"affiliation":5,"role":29},"Anna Karlsson, MD",[37,42],{"name":28,"role":38,"phone":39,"phoneExt":40,"email":41},"CONTACT","+46101030000","3187","preben.kjolhede@regionostergotland.se",{"name":35,"role":38,"phone":39,"phoneExt":43,"email":44},"3117","anna.br.karlsson@regionostergotland.se",[46,72,91,112,131,150,164,181],{"facility":47,"status":48,"city":49,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"Department of Obstetrics and Gynecology, Highland Hospital","RECRUITING","Eksjö","575 81","Sweden","SE",{"type":54,"coordinates":55},"Point",[56,57],14.97205,57.66643,{"lat":57,"lon":56},[60,64,67,70],{"name":61,"role":38,"phone":62,"phoneExt":17,"email":63},"Christopher Allen, MD","+46102410000","christopher.allen@rjl.se",{"name":65,"role":66,"phone":17,"phoneExt":17,"email":17},"Malena Tiefenthal Thrane, MD","PRINCIPAL_INVESTIGATOR",{"name":68,"role":69,"phone":17,"phoneExt":17,"email":17},"Catarina Notelid Claus, MD","SUB_INVESTIGATOR",{"name":71,"role":69,"phone":17,"phoneExt":17,"email":17},"Hanna Reimerson, MD",{"facility":73,"status":48,"city":74,"state":74,"zip":75,"country":51,"countryCode":52,"cosmosGeoPoint":76,"geoPoint":80,"contacts":81},"Department of Oncology, Sahlgrenska University Hospital","Gothenburg","41345",{"type":54,"coordinates":77},[78,79],11.96679,57.70716,{"lat":79,"lon":78},[82,86,87,89],{"name":83,"role":38,"phone":84,"phoneExt":17,"email":85},"Karin Bergmark, MD, PhD","+46313421000","Karin.Bergmark@vgregion.se",{"name":83,"role":66,"phone":17,"phoneExt":17,"email":17},{"name":88,"role":69,"phone":17,"phoneExt":17,"email":17},"Pernilla Dahm-Kähler, MD, PhD",{"name":90,"role":69,"phone":17,"phoneExt":17,"email":17},"Boglarka Fekete, MD",{"facility":92,"status":48,"city":93,"state":94,"zip":95,"country":51,"countryCode":52,"cosmosGeoPoint":96,"geoPoint":100,"contacts":101},"Department of Obstetrics and Gynecology, Ryhov County Hospital","Jönköping","Jönköping County","55305",{"type":54,"coordinates":97},[98,99],14.15618,57.78145,{"lat":99,"lon":98},[102,105,106,108,110],{"name":103,"role":38,"phone":62,"phoneExt":17,"email":104},"Laila Falknäs, MD","laila.falknas@rjl.se",{"name":103,"role":66,"phone":17,"phoneExt":17,"email":17},{"name":107,"role":69,"phone":17,"phoneExt":17,"email":17},"Christiane Sackbrook, MD",{"name":109,"role":69,"phone":17,"phoneExt":17,"email":17},"Anke Zbikowski, MD",{"name":111,"role":69,"phone":17,"phoneExt":17,"email":17},"Narmin Rasul, MD",{"facility":113,"status":48,"city":114,"state":114,"zip":115,"country":51,"countryCode":52,"cosmosGeoPoint":116,"geoPoint":120,"contacts":121},"Department of Oncology, Linköping University Hospital","Linköping","58185",{"type":54,"coordinates":117},[118,119],15.62157,58.41086,{"lat":119,"lon":118},[122,124,125,127,129],{"name":31,"role":38,"phone":39,"phoneExt":17,"email":123},"gabriel.lindahl@regionostergotland.se",{"name":31,"role":66,"phone":17,"phoneExt":17,"email":17},{"name":126,"role":69,"phone":17,"phoneExt":17,"email":17},"Annika Holmquist, MD, PhD",{"name":128,"role":69,"phone":17,"phoneExt":17,"email":17},"Oscar Derke, MD",{"name":130,"role":69,"phone":17,"phoneExt":17,"email":17},"Tommy Leijon, MD",{"facility":132,"status":48,"city":133,"state":133,"zip":134,"country":51,"countryCode":52,"cosmosGeoPoint":135,"geoPoint":139,"contacts":140},"Department of Obstetrics and Gynaecology, Norrland University Hospital","Umeå","90719",{"type":54,"coordinates":136},[137,138],20.25972,63.82842,{"lat":138,"lon":137},[141,145,146,148],{"name":142,"role":38,"phone":143,"phoneExt":17,"email":144},"Ulrika Ottander, MD, PhD","+46907850000","Ulrika.Ottander@umu.se",{"name":142,"role":66,"phone":17,"phoneExt":17,"email":17},{"name":147,"role":69,"phone":17,"phoneExt":17,"email":17},"Charlotte Öfverman, MD, PhD",{"name":149,"role":69,"phone":17,"phoneExt":17,"email":17},"Pernilla Israelsson, MD, PhD",{"facility":151,"status":48,"city":152,"state":152,"zip":153,"country":51,"countryCode":52,"cosmosGeoPoint":154,"geoPoint":158,"contacts":159},"Department of Obstetrics and Gynecology, Värnamo Hospital","Värnamo","33152",{"type":54,"coordinates":155},[156,157],14.04001,57.18604,{"lat":157,"lon":156},[160,163],{"name":161,"role":38,"phone":62,"phoneExt":17,"email":162},"Shefqet Halili, MD","shefqet.halili@rjl.se",{"name":161,"role":66,"phone":17,"phoneExt":17,"email":17},{"facility":165,"status":48,"city":166,"state":166,"zip":167,"country":51,"countryCode":52,"cosmosGeoPoint":168,"geoPoint":172,"contacts":173},"Department of Obstetrics and Gynecology, Västervik Hospital","Västervik","593 81",{"type":54,"coordinates":169},[170,171],16.63733,57.7584,{"lat":171,"lon":170},[174,178,179],{"name":175,"role":38,"phone":176,"phoneExt":17,"email":177},"Anders Rosenmüller, MD","+4649086000","anders.rosenmuller@regionkalmar.se",{"name":175,"role":66,"phone":17,"phoneExt":17,"email":17},{"name":180,"role":69,"phone":17,"phoneExt":17,"email":17},"Helena Avenström, MD",{"facility":182,"status":183,"city":114,"state":184,"zip":115,"country":51,"countryCode":52,"cosmosGeoPoint":185,"geoPoint":187,"contacts":17},"Department of Obstetrics and Gynecology, University Hospital","ACTIVE_NOT_RECRUITING","Östergötland County",{"type":54,"coordinates":186},[118,119],{"lat":119,"lon":118},{"type":66,"investigatorFullName":189,"investigatorTitle":190,"investigatorAffiliation":5,"oldNameTitle":17,"oldOrganization":17},"Preben Kjolhede, MD, professor","Professor, senior consultant",[192,195,197,199],{"name":193,"class":194},"Region Jönköping County","OTHER_GOV",{"name":196,"class":6},"Västervik Hospital",{"name":198,"class":194},"Vastra Gotaland Region",{"name":200,"class":194},"Region Västerbotten","100461124","phase-2-tinzaparin-and-biomarkers-after-neoadjuvant-treatment-of-ovarian-cancer-100461124",false,"NCT05284552","Tinzaparin And Biomarkers After Neoadjuvant Treatment of Ovarian Cancer","The Effect of Tinzaparin on Biomarkers in FIGO Stage III-IV Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy - A Randomized Pilot Study","Inclusion Criteria:\n\n* The subject has given written consent to participate in the study.\n* Age 18 and above\n* Epithelial ovarian, fallopian tube or peritoneal cancer, or abdominal cancer where a biopsy indicates an origin from the ovary, fallopian tube or peritoneum.\n* Histology diagnosis of either high grade serous carcinoma, endometroid carcinoma or clear cell carcinoma.\n* FIGO stage III-IV disease.\n* Planned for platinum-based chemotherapy\n* Prior to start of NACT pregnancy should be ruled out by menstrual history or in unclear cases by a urine hCG test.\n* Women of childbearing potential should use a safe birth control method (combined hormonal contraception, progesterone only hormonal contraception, intra uterine device, bilateral tubal occlusion, vasectomized partner, sexual abstinence, male or female condom, diaphragm with spermicide).\n* WHO Performance Status 0-2\n* Weight 50-150 kg\n* CA-125-level ≥250 kIE\u002FL at diagnosis\n\nExclusion Criteria:\n\n* Concomitant treatment with heparins, low molecular weight heparins, warfarin or non-vitamin K antagonist oral anticoagulants. Platelet inhibitors are allowed.\n* Treatment with heparins, low molecular weight heparins or non-vitamin K antagonist oral anticoagulants within the last year.\n* Known or suspected allergies against any product included in the study\n* Ongoing pregnancy, independent of gestational age. Breastfeeding or planned pregnancy\n* EOC disclosed at Cesarean section\n* Abdominal surgery or other major surgery within the last year\n* Mental inability, reluctance or language difficulties that result in difficulty understanding the meaning of study participation\n* Treatment or disease which, according to the investigator, can affect treatment or study results\n* Known brain metastasis\n* Participation or recent participation (within the last 30 days) in a clinical study with an investigational product\n* Ongoing treatment of thromboembolic disease.\n* Thromboembolic disease within the last year.\n* Hypersensitivity to the active substance (tinzaparin) or any of the excipients.\n* Serious hemorrhage or conditions predisposing to serious hemorrhage. Serious hemorrhage is defined as fulfilling any one of these three criteria:\n\n  1. occurs in a critical area or organ (e.g. intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, intra-uterine or intramuscular with compartment syndrome),\n  2. causes a fall in hemoglobin level of 20 g\u002FL (1.24 mmol\u002FL) or more, or\n  3. leads to transfusion of two or more units of whole blood or red blood cells.\n* Severe coagulation disorder.\n* Acute gastro duodenal ulcer.\n* Septic endocarditis.\n* Previous heparin-induced thrombocytopenia.\n* WHO Performance Status \\>2.\n* E-GFR \\\u003C30ml\u002Fmin (analyzed no more than 14 days before start of treatment with investigational product)\n* Platelets \\\u003C100 x10\\^9\u002FL (analyzed no more than 14 days before start of treatment with investigational product)\n* Treatment for other known malignancy within the last year (except basal cell carcinoma)","FEMALE","18 Years",{"count":211,"type":212},40,"ESTIMATED","INTERVENTIONAL",[215],"PHASE2","Background:\n\nPrevious findings have indicated antineoplastic properties of tinzaparin (Innohep®), a commonly used anti-coagulant. Earlier studies have mainly investigated the antineoplastic effects of tinzaparin in animal models and in human cell-lines. In this pilot study the aim is to examine the potential antitumoral effects of tinzaparin in vivo in women with epithelial ovarian cancer (EOC).\n\nStudy objectives:\n\nPrimary objective: The primary objective of the study is to evaluate the effects of tinzaparin on changes in levels of CA-125 in EOC patients who receive neoadjuvant chemotherapy (NACT).\n\nSecondary objectives: The secondary objective of the study is to explore the impact of tinzaparin on the dynamic of a spectrum of immunological and coagulation factors in EOC patients who receive NACT. Besides, the compliance of tinzaparin injections and adverse events caused by tinzaparin will be described.",[218],"Epithelial Ovarian Cancer",[220,221,222],"Tinzaparin","Neoadjuvant chemotherapy","FIGO stage III-IV","2026-05-06",{"date":225,"type":226},"2026-05-11","ACTUAL",{"date":228,"type":226},"2022-07-12",{"date":230,"type":212},"2027-12",{"name":5,"class":6},8]